How to buy Paratek Pharmaceuticals stock

Paratek Pharmaceuticals, Inc is a biotechnology business based in the US. Paratek Pharmaceuticals shares (PRTK) are listed on the NASDAQ and all prices are listed in US Dollars. Paratek Pharmaceuticals employs 101 staff and has a trailing 12-month revenue of around USD$39.9 million.

How to buy shares in Paratek Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Paratek Pharmaceuticals. Find the stock by name or ticker symbol: PRTK. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Paratek Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Paratek Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Paratek Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced traders

Interactive Brokers

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active traders. We picked Interactive Brokers for this category because it offers advanced tools and low fees for active investors and pros. The simpler IBKR Lite platform is aimed at less-active investors, but all users older than 21 must meet a $20,000 liquid net worth requirement for a cash account.

What's in this guide?

1. PRTK shares summary
2. Compare share dealing platforms
3. Is PRTK stock a buy or sell?
4. Stock performance over time
5. Can I short PRTK shares?
6. Paratek Pharmaceuticals's financials
7. How volatile are PRTK shares?
8. Does Paratek Pharmaceuticals pay a dividend?
9. Have PRTK shares ever split?
10. Other common questions

Paratek Pharmaceuticals share price

Use our graph to track the performance of PRTK stocks over time.

Paratek Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-02-24.

52-week range	USD$2.5 - USD$8.75
50-day moving average	USD$7.0239
200-day moving average	USD$5.9421
Wall St. target price	USD$20.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.845

Buy Paratek Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Moomoo		$0 for US stocks	Stocks, Options, ETFs	$0		N/A	Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Paratek Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Paratek Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting Paratek Pharmaceuticals shares

There are currently 4.0 million Paratek Pharmaceuticals shares held short by investors – that's known as Paratek Pharmaceuticals's "short interest". This figure is 1.1% down from 4.1 million last month.

There are a few different ways that this level of interest in shorting Paratek Pharmaceuticals shares can be evaluated.

Paratek Pharmaceuticals's "short interest ratio" (SIR)

Paratek Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Paratek Pharmaceuticals shares currently shorted divided by the average quantity of Paratek Pharmaceuticals shares traded daily (recently around 351943.61888112). Paratek Pharmaceuticals's SIR currently stands at 11.44. In other words for every 100,000 Paratek Pharmaceuticals shares traded daily on the market, roughly 11440 shares are currently held short.

However Paratek Pharmaceuticals's short interest can also be evaluated against the total number of Paratek Pharmaceuticals shares, or, against the total number of tradable Paratek Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Paratek Pharmaceuticals's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Paratek Pharmaceuticals shares in existence, roughly 90 shares are currently held short) or 0.0924% of the tradable shares (for every 100,000 tradable Paratek Pharmaceuticals shares, roughly 92 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Paratek Pharmaceuticals.

Find out more about how you can short Paratek Pharmaceuticals stock.

Have Paratek Pharmaceuticals's shares ever split?

Paratek Pharmaceuticals's shares were split on a 1:12 basis on 31 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Paratek Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Paratek Pharmaceuticals shares which in turn could have impacted Paratek Pharmaceuticals's share price.

Paratek Pharmaceuticals share price volatility

Over the last 12 months, Paratek Pharmaceuticals's shares have ranged in value from as little as $2.5 up to $8.75. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Paratek Pharmaceuticals's is 1.5283. This would suggest that Paratek Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Paratek Pharmaceuticals overview

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Frequently asked questions

• What percentage of Paratek Pharmaceuticals is owned by insiders or institutions?

  Currently 9.044% of Paratek Pharmaceuticals shares are held by insiders and 52.649% by institutions.

• How many people work for Paratek Pharmaceuticals?

  Latest data suggests 101 work at Paratek Pharmaceuticals.

• When does the fiscal year end for Paratek Pharmaceuticals?

  Paratek Pharmaceuticals's fiscal year ends in December.

• Where is Paratek Pharmaceuticals based?

  Paratek Pharmaceuticals's address is: 75 Park Plaza, Boston, MA, United States, 02116

• What is Paratek Pharmaceuticals's ISIN number?

  Paratek Pharmaceuticals's international securities identification number is: US6993743029

• What is Paratek Pharmaceuticals's CUSIP number?

  Paratek Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 66987B103